1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts

Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts

  • October 2016
  • -
  • Currentpartnering
  • -
  • 1000 pages

Summary

Table of Contents

Search Inside

The Global Personalized Medicine Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Personalized Medicine agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Personalized Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Personalized Medicine partnering deals.

The report presents financial deal term values for Personalized Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Personalized Medicine partnering field; both the leading deal values and most active Personalized Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,370 online deal records of actual Personalized Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Personalized Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Personalized Medicine partnering deals signed and announced since Jan 2010. The chapter is organized by specific Personalized Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Personalized Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine technologies and products.

Key benefits

Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Personalized Medicine deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Personalized Medicine agreements with numerous real life case studies
Detailed access to actual Personalized Medicine contracts entered into by leading biopharma companies
Identify most active Personalized Medicine dealmakers since 2010
Insight into terms included in a Personalized Medicine partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Personalized Medicine trends and structure of deals entered into by leading companies worldwide.

Personalized Medicine Partnering Terms and Agreements includes:

Trends in Personalized Medicine dealmaking in the biopharma industry since 2010
Analysis of Personalized Medicine deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Personalized Medicine deals
Access to Personalized Medicine contract documents
Leading Personalized Medicine deals by value since 2010
Most active Personalized Medicine dealmakers since 2010

In Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Personalized Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,370 Personalized Medicine deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Non-alcoholic Steatohepatitis Biomarkers Market and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Non-alcoholic Steatohepatitis Biomarkers Market and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...

Biomarkers Market by Product, Type, Disease Indication, Application - Global Forecast to 2021

Biomarkers Market by Product, Type, Disease Indication, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global biomarkers market is estimated to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Increasing diagnostic applications of biomarkers, increasing ...

Next-Generation Sequencing (NGS) Market by Product (Hiseq, Miseq, Hiseq X Ten/X Five, NextSeq500, Ion Proton, PGM, Ions5, PacBio RSII), Services (Targeted, RNA, Exome, De Novo), & Application (Diagnostics, Biomarker, Agriculture) - Global Forecasts to 202

Next-Generation Sequencing (NGS) Market by Product (Hiseq, Miseq, Hiseq X Ten/X Five, NextSeq500, Ion Proton, PGM, Ions5, PacBio RSII), Services (Targeted, RNA, Exome, De Novo), & Application (Diagnostics, Biomarker, Agriculture) - Global Forecasts to 202

  • $ 5650
  • Industry report
  • April 2017
  • by MarketsandMarkets

The global next-generation sequencing market is estimated to register a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 billion by 2022. Factors such as technological advancements in NGS platforms, ...


Download Unlimited Documents from Trusted Public Sources

Genomics Industry in the US

  • March 2017
    8 pages
  • Genomics  

  • United States  

    Asia  

View report >

Genetic Industry in Australia

  • February 2017
    79 pages
  • Genetic  

    Health Care Pro...  

    Clinic  

  • Australia  

View report >

Cancer Statistics

  • February 2017
    6 pages
  • Cancer  

  • United Kingdom  

    United States  

View report >

Oleochemicals Industry

3 months ago

Related Market Segments :

Biomarker
Cancer

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.